IM-91

N/A

Report date: 2023/02/22 10:38:26

Base Information

Drug NameIM-91
Drug Alias NameIM-91
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsAnti-IL13RA2
TargetsInterleukin-13 receptor subunit alpha-2
Therapy Area/IndicationsGlioblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesImunopharm Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesImunopharm Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsGlioblastoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A